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Abstract: Human pancreatic cancer has a very poor prognosis with an overall five-year survival
rate of less than 5% and an average median survival time of six months. This is largely due to
metastatic disease, which is already present in the majority of patients when diagnosed. Although
our understanding of the molecular events underlying multi-step carcinogenesis in pancreatic cancer
has steadily increased, translation into more effective therapeutic approaches has been inefficient
in recent decades. Therefore, it is imperative that novel and targeted approaches are designed to
facilitate the early detection and treatment of pancreatic cancer. Presently, there are numerous ongoing
studies investigating the types of genomic variations in pancreatic cancer and their impact on tumor
initiation and growth, as well as prognosis. This has led to the development of therapeutics to target
these genetic variations for clinical benefit. Thus far, there have been minimal clinical successes
directly targeting these genomic alterations; however research is ongoing to ultimately discover
an innovative approach to tackle this devastating disease. This review will discuss the genomic
variations in pancreatic cancer, and the resulting potential diagnostic and therapeutic implications.
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1. Introduction
Over the last few decades, pancreatic cancer has consistently remained one of the most lethal
and challenging cancers to diagnose and treat [1]. Although significant advances have been made
in the domain of cancer treatment to enhance survival rates for other solid tumors including breast,
colorectal, prostate and renal, mortality rates for pancreatic cancer patients remain extraordinarily high.
Additionally, pancreatic cancer statistics have proven to be disappointing with 90,100 new pancreatic
cancer cases and 79,400 deaths in China in 2015 [2], as well as 53,070 new pancreatic cancer cases
and 41,780 estimated deaths in United States in 2016 [3]. Moreover, prognoses for patients remain
devastatingly poor. In particular, patients presenting with locally advanced cancer have a median
survival time of 8–12 months, whereas those presenting with distant metastases have an exceedingly
worse prognosis with a median survival time of 3–6 months. As well as this, five-year survival
rates are still less than 5% despite 50 years of research and therapeutic development [4,5]. Extensive
research has categorized pancreatic cancer into two main subtypes: exocrine and neuroendocrine types.
Pancreatic ductal adenocarcinoma (PDAC) belongs to the exocrine group and is the most common
type, dominating about 85% of all pancreatic cancer cases [1].
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At present, the majority of patients present with locally advanced or metastatic pancreatic
cancer. Delayed diagnosis is a result of a multitude of factors, including non-specific symptoms
such as anorexia, jaundice and gastric outlet obstructions. Additionally, there are no effective
screening methods for low-risk cohorts, which hinders early detection, as hereditary factors only
contribute to 5–10% of pancreatic cancer cases. Thus, patients present at a late stage in their disease,
which reduces treatment options and complicates manageability of the disease [5,6]. Currently,
the only potential curative option is surgery, however, only a mere 15–20% of patients are able to
undergo pancreatectomy when diagnosed. Coupled with the fact that over 80% of patients relapse
after resection, surgery does not constitute a promising treatment option [7]. Moreover, there are
limited chemotherapy agents that have clinical benefits in pancreatic cancer and response rates vary
significantly. Presently, gemcitabine-based treatments remain the first-line therapy for pancreatic
cancer patients with gemcitabine combined alongside erlotinib being the standard treatment regimen
for patients with advanced disease. However, clinical outcomes are still marginal. Even within the
metastatic setting, chemotherapy regimens have rendered only modest improvements in survival
rates. For example, gemcitabine combined with nab-paclitaxel demonstrated minor improvements
in overall survival with a median survival of one year for patients with advanced disease [4].
Additionally, FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin) has recently also
been implicated in metastatic disease with marginal clinical success [8]. A potential explanation for late
diagnosis is that molecular carcinogenesis of PDAC occurs over decades, through stepwise progression
from a preinvasive stage, pancreatic intraepithelial neoplasia (PanIN), to invasive pancreatic cancer.
This evolution correlates with accumulation of genetic aberrations and other molecular irregularities [9].
Pancreatic cancer is characterized by four major driver genes: Kirsten rat sarcoma viral oncogene
homolog (KRAS), Cyclin-dependent kinase Inhibitor 2A (CDKN2A), Mothers against decapentaplegic
homolog 4 (SMAD4) and Tumor protein p53 (TP53). KRAS is of particular importance as the activating
point mutation in the KRAS oncogene found in 90% of pancreatic cancer cases and it comprises
one of the initial genetic mutations in non-cancerous precursor lesions [10]. Additionally, the tumor
suppressor gene CDKN2A, which regulates G1 to S phase in the cell cycle, undergoes a mutational
inactivation. Finally, SMAD4 and TP53 are primarily found in higher-grade lesions [5].
The dismal survival rates for pancreatic cancer, as well as the disappointing response rates and
high levels of resistance to standard treatments has reinforced the urgent and crucial need for novel
treatments for pancreatic cancer patients. This has forged an avenue for the study of genomic variations
on pancreatic cancer, which have been demonstrated to play a role in initiation, development and
invasion of the disease. Thus, these genetic alterations may provide insight into targets for diagnosis
and innovative and effective treatments for patients. In line with this, next-generation DNA sequencing
technologies have revolutionized the study of genomic variations in cancer and are pioneering the
developmental direction of precision medicine. This technology provides the advantage of increasing
the speed of gaining results and reducing costs. Fully analyzing the genomic landscapes of tumors is
highly beneficial as this can pave the way for improved diagnosis and prognosis. Moreover, there are
many institutions dedicated to characterizing the genomic and transcriptomic landscapes of cancer,
including The Cancer Genome Atlas and the International Cancer Genome Consortium, which should
hasten progress in this field.
This review will discuss the genomic variations in pancreatic cancer, and the diagnostic as well as
therapeutic implications of this will be provided.
2. Types of Genomic Variations
Through whole-genome and deep-exome sequencing, genomic multiplicities of pancreatic
cancer, such as copy number alterations, point mutations and indels, chromosomal aberrations and
epigenetic changes have been identified. Interestingly, pancreatic cancer has fewer mutations in
comparison to other cancer types [11]. One potential explanation is that the initiating cells of pancreatic
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cancer undergo fewer divisions. In this part, we discuss a variety of genomic variations within
pancreatic cancer.
2.1. Chromosomal Aberrations
Chromosomal aberrations in pancreatic cancer include loss, gain and structural rearrangements.
It has been demonstrated that losses of chromosome 18 (78%), 17 (56%), 6 (44%), 21 (42%),
22 (42%), Y (36%), 4 (33%) and gain of chromosome 20 (28%) are very common in pancreatic
adenocarcinomas [12]. Furthermore, there are three types of structural rearrangements: translocations,
gene fusions and inversions. However, structural rearrangements are relatively uncommon in the
pancreatic cancer genome [13,14]. Somatic structural variants were identified with the qSV package
in 100 pancreatic cancer patients, totally, 11,868 somatic structural variants were identified and every
individual has about 119 variants on average [14].
2.2. Copy Number Variations
Copy number variations (CNV) include: amplifications, deletions and loss of heterozygous (LOH)
and are prevalent in the whole genome of pancreatic cancer [15–17]. High levels of amplifications
at 7q21.3–q22.1 and 19q13.2 and homozygous deletions at 1p33–p32.3, 1p22.1, 1q22, 3q27.2, 6p22.3,
6p21.31, 12q13.2, 17p13.2, 17q21.31 and 22q13.1 have been reported from 93 pancreatic carcinoma
patients in China using Array-Based Comparative Genomic Hybridization [18]. Furthermore, analysis
of genomic sequences of 456 patients in the Australian Pancreatic Cancer Genome Initiative (APGI),
revealed 50 regions of amplifications and 73 regions of deletions [13]. The alternated regions contained
oncogenes, such as KRAS, MET, NOTCH, and GATA6 and tumor suppressor genes, including CDKN2A,
SMAD4, and TP53 [13,16,19]. The number of CNV is relative to the postoperative survival, thus usually
patients with more CNV have shorter survival rates [15,20].
2.3. Point Mutations and Indels
Point mutations and indels are common in the whole genome of pancreatic cancer [14,17,21–24],
with many oncogenes and tumor suppressor genes existing in their mutated forms. KRAS, TP53,
CDKN2A and SMAD4 are most prevalent mutated genes in pancreatic cancer [14,21,25–30]. KRAS is
activated by point mutations in 95% of invasive ductal adenocarcinomas. The KRAS point mutations
present early in pancreatic neoplasia, and almost exclusively target three codons (12, 13 and 61), which
are relatively easy to identify. KRAS mutations can be used as diagnostic markers to detect early
curable pancreatic neoplasia [25,29]. Additionally, the TP53 tumor suppressor gene on chromosome
17p has lost its function in 75% of pancreatic cancers [27]. Moreover, another tumor suppressor
gene on chromosome 9pP16, CDKN2A is inactivated in about 95% of pancreatic cancers [26,28,31].
The fourth major alteration of tumor suppressor gene on chromosome 18q is SMAD4 (previously
called DPC4) [30].
2.4. Epigenetic Changes
The major epigenetic changes in pancreatic cancers include DNA methylation and microRNA
profiles [16]. Both of these can potentially alter gene expressions in cancer cells. In particular,
many important genes involved in the progression of pancreatic cancer have been hypermethylated,
such as RARB [32], APC [33], TSLC/IGSF4 [34], SOCS-1 [35], CCND2 [36], RASSF1A [37], WWOX [38],
RUNX3 [39], CDH13 [40], HHIP [41], SLC5A8 [42] and P16/CDKN2A [32,43,44]. Hypermethylated
promoters of tumor suppressor genes result in their inactivation and facilitate tumorigenesis.
In addition, 18–24 bases long microRNAs (miRNAs) can regulate the stability and translational
efficiency of the targeting mRNAs and are involved in cell proliferation, cell death and tumorigenesis [45].
The miRNA profiles are unique in various cancer types [46]. A group of 112 miRNAs, which vary among
pancreatic cancer tissues, normal and benign tissues, including in pancreatitis have been identified [47].
miR-217 and miR-196a expression profiles can be used in differentiating pancreatic cancer tissue from
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normal pancreas tissues and chronic pancreatitis [48]. Furthermore, miR-21 was found significantly
up-regulated in 20 pancreatic carcinomas and six cancer cell lines compared with the coupled benign
tissues and normal pancreas [49]. miR-196a-2 was identified to be a predictor of survival of pancreatic
tumor patients [50]. Overall, abnormalities in microRNA expression within endocrine and acinar
pancreatic tumors are associated with distinctive pathologic features and clinical behaviors.
3. Contribution of Genomic Instability to Pancreatic Carcinogenesis
Through decades of research, scientists have demonstrated that tumors possess ten unifying
traits: sustained proliferation signaling; growth suppressor evasion; cell death resistance; enabling
of replicative immortality; induction of angiogenesis; activation of invasion and metastasis; evasion
of immune destruction; deregulated cellular energetics; tumor promoting inflammation and genome
instability and mutation [51].
Genomic instability and mutation is an enabling characteristic because it can induce the acquisition
of other hallmarks of cancer (Figure 1). Several different pathways contribute to one trait acquisition,
resulting in various pathways becoming activated to facilitate carcinogenesis when one pathway is
blocked. Mutations of some genes participate in more than one trait acquisition. In this part, we discuss
the contribution of genomic variations to pancreatic carcinogenesis (summarized in Table 1).
Figure 1. Contributions of genomic variations to pancreatic carcinogenesis
Table 1. Summarization of genomic variation pathways that contribute to pancreatic carcinogenesis.
Pancreatic Tumor Traits Genomic Variation Pathways
Sustained proliferation signaling PI3K/AKT; KRAS; PTEN
Growth suppressor evasion TP53; RB; NF2/MERLIN; LKB1
Cell death resistance CCND1; BCL2; TP53; BRCA2; miRNA216a/BECLIN1
Enabling of replicative immortality PCDH10/hTERT
Induction of angiogenesis ETS1/PIM3
Activation of invasion and metastasis SNAIL; SLUG; miRNA-1271/TWIST; EST1/ZEB2
Evasion of immune destruction HIF1α/MIC; MMP9
Deregulated cellular energetics KRAS/IDH; FH; SDH
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3.1. Sustained Proliferation
In normal tissues, the production and release of growth-promoting signals are carefully
controlled to ensure homeostasis of cell number and maintain normal tissue architecture and
function. In pancreatic cancer cells, control of these signals is lost. Somatic mutations such as
phosphoinositide3-kinase (PI3K)-AKT/PKB [52,53] and KRAS [54] constitutively activate proliferation
signaling. Mutations in PTEN [53] disrupt the negative feedback of proliferation signaling. All of these
genetic mutations contribute to sustained proliferation of pancreatic cancer cells.
3.2. Evading Growth Suppression
In normal cells, growth suppression signals inhibit excessive growth; on the contrary, cancer cells
have the ability to evade growth suppression. Mutations in tumor suppressor genes such as TP53 and
RB [55–57] that participate in the inhibition of cell cycle progression result in cells losing control of
growth suppression. As well as this, decreased expression of NF2 [58,59] and LKB1 [60–62] genes in
pancreatic tumor and cancer cell lines also contribute to evading growth suppression. In particular,
the NF2 gene encodes Merlin, a member of the band 4.1 family of cytoskeleton-associated proteins,
functions as a tumor suppressor and is a critical mediator of contact dependent inhibition of growth
through signals from the extracellular matrix and FOXM1/WNT/β-CATENIN pathway in pancreatic
cancer [63]. It has been elucidated that LKB1 (liver kinase B1) can regulate cell proliferation and polarity
and its expression influences PDAC patients overall survival.
3.3. Resisting Cell Death
Cancer cells can avoid programmed cell death by abnormal expression of oncogenes such as
CCND1 [64], BCL-2 [65] and inactivation of tumor suppressor genes such as TP53 and BRCA2 [66].
Previous research demonstrated that autophagy can protect cancer cells from death induced
by cetuximab [67]. When depriving nutrients or growth factors that govern nutrient uptake,
cell autophagy, a regulated catabolic process, will happen. Autophagy is a double-edged sword
in cancer as it participates both in cytoprotection and in cell death [68,69]. The presence of hypoxia
in pancreatic cancer induces autophagy in cancer cells [70]. BECLIN1, a critical autophagic gene,
mediates autophagy of pancreatic cancer cells. miRNA-216a targets BECLIN1 by directly interacting
with its 3′-untranslated region to inhibit it [71]. In pancreatic cancer, miRNA-216a is significantly
downregulated and cells can antagonize death through BECLIN1-mediated autophagy [71,72].
3.4. Enabling Replicative Immortality
Replicative immortality depends on the stability of telomeres as it maintains the integrity
of chromosomes and inhibits DNA degradation. In normal cells, telomeres are consumed and
shortened in each DNA replication process. Till the threshold of the telomere length, cells go to
senescence. Telomerase, composed of template RNA (transcript from hTR gene), telomere related
protein 1 (TP1) and telomerase reverse transcriptase (hTERT), is responsible for maintaining the
length of telomeres. In normal mature somatic cells, the activity of telomerase cannot be detected.
Protocadherin 10 (PCDH10), a tumor suppressor, was found to negatively regulate telomerase activity
through interaction with hTERT [73]. Whereas, the promoter of PCDH10 was hypermethylated and
its expression was decreased in pancreatic cancer [74] thus elevating telomerase activity to enable
replicative immortality of cancer cells [75,76].
3.5. Inducing Angiogenesis
Erythroblastosis virus E26 oncogene homolog 1 (ETS-1), a transcription factor, was shown to be
aberrantly expressed in pancreatic cancer by an unknown mechanism. It increased the angiogenesis of
pancreatic cancer cells partially through transcriptional regulation of PIM3, a proto-oncogene with
serine/threonine kinase activity [77,78]. PIM3 is constitutively expressed in pancreatic cancer, where
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it not only inhibits cell apoptosis by phosphorylating Bad [79] but also promotes pancreatic tumor
neoangiogenesis [80].
3.6. Activating Invasion and Metastasis
Epithelial-mesenchymal transition (EMT) is a crucial way for tumor invasion and metastasis.
Transcription factors SNAIL, SLUG, TWIST and ZEB1/2 were identified in orchestrating EMT [81–84].
Furthermore, miRNA-1271 has been found to have significantly decreased levels in pancreatic cancer
tissues. It has been shown to increase EMT through inhibiting the expression of TWIST and ZEB1 [85].
EST-1 was also identified as a regulator of EMT in pancreatic cancer cells through ZEB2, thus increasing
the motility of cancer cells [86,87].
3.7. Deregulating Cellular Energetics
Pancreatic cancer cells are deprived of oxygen and nutrients, which forces them to activate
metabolic pathways to provide energy and maintain growth. Previous findings have confirmed that
PDAC has an elevated glucose catabolism switch towards lactate production [88–91]. The mechanisms
resulting in this are partially due to mutated KRAS. The KRAS gene regulates numerous enzymes
involved in glutamine catabolism and glucose channeling towards glycolysis and Pentose Phosphate
Pathway (PPP) (responsible for protein glycosylation and ribose production). KRASG12D mutation
leads to mutations in its regulated metabolic enzymes. This results in activation of glucose and
glutamine metabolisms through gain of activity of isocitrate dehydrogenase (IDH) and loss of activity
of fumaratehydratase (FH) and succinate dehydrogenase(SDH) [92,93]. IDH, FH and SDH are major
enzymes involved in the Krebs cycle.
3.8. Avoiding Immune Destruction
The immune system possesses the ability to regulate tumor progression whereby tumors are
able to proliferate by escaping immune destruction. Significantly higher levels of hypoxia-inducible
1α (HIF-1α) have been identified in pancreatic carcinoma in comparison to chronic pancreatitis and
normal pancreatic tissues. HIF-1α is inversely correlated with major histocompatibility complex
class I chain-related (MIC) genes and is considered to be involved in tumor immune evasion [94].
Additionally, natural killer (NK) cells are important in non-specific immunoresponses in pancreatic
cancer. Furthermore, elevated MMP9 expression in pancreatic cancer cells mediates natural killer cells
dysfunction and facilitates immune evasion [95].
4. Effects of Pancreatic Cancer Genetics on Host Immunity
Genetic changes in pancreatic cancers have the ability to promote an immunosuppressive
microenvironment to accelerate proliferation and progression of the tumor [96]. In this context,
oncogenic KRAS, one of the major driver genes, is of particular importance. The oncogene drives
immune privilege within the pancreatic tumor microenvironment, thus enabling pancreatic cancer
progression through multiple mechanisms [97,98]. Of particular relevance to host anti-tumor immunity
is the role of KRAS in upregulating granulocyte-macrophage colony-stimulating factor (GM-CSF).
GM-CSF has been found at significantly high levels in many human PDAC cells and many studies
have highlighted that oncogenic KRAS-driven GM-CSF expression in pancreatic intraepithelial
neoplasia (PanIN) and invasive pancreatic cancer cells promote an influx of immunosuppressive
myeloid cells, which inhibit adaptive immunity [99,100]. For example, Pylayeva-Gupta et al. recently
reported that activation of mutated KRAS in pancreatic ductal cells promotes GM-CSF production.
This leads to clonal expansion of immunosuppressive Gr1+ CD11b+ myeloid cells which are involved
in cancer-associated inflammatory reactions. This in turn results in suppression of anti-tumor
CD8+T cell-driven immunity [101]. Similarly, Bayne et al., demonstrated the equivalent correlation
between GM-CSF and evasion of host anti-tumor T cell immunity through accumulation of Gr1+
CD11b+ myeloid cells in spontaneous murine models of PDAC [102]. Furthermore, McAllister et al.,
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also indicated a role for mutant KRAS in promoting IL-17 production which was shown to be necessary
for the development and progression of PanIN. The study demonstrated that mutant KRASG12D
in vivo in the Mist1CreERT2/+; LSL-KRASG12D murine genetic model of PanIN drives expression of
functional IL-17 receptors on PanIN epithelial cells. The oncogenic KRAS also induces infiltration of
IL-17-producing immune cells, CD4+T and γδT within the pancreatic stroma, which stimulates PanIN
initiation and development [103]. Overall, these findings implicate oncogenic KRAS and other genes
that are stimulated through KRAS signaling pathways as promising targets for designing effective
immunotherapies against pancreatic cancer.
In addition, Zhou et al. recently demonstrated that overexpression of human leucocyte antigen
G (HLA-G) correlated with immune suppression and poor prognosis in pancreatic cancer patients.
The study highlighted that HLA-G was found to be expressed at significantly higher levels in tumor
tissues compared to normal tissues and this was associated with decreased levels of intratumoral
CD3-positive tumor infiltrating lymphocytes [104]. The underlying mechanisms are not yet clarified.
5. Implications of Genomic Variations on Pancreatic Cancer Diagnosis and Treatment
The need for effective therapeutics for pancreatic cancer is extremely vital as this malignancy
has one of the greatest rates of mortality in comparison to other types of cancer. In clinics, pancreatic
cancer patients are treated with a stochastic approach based on the expertise and previous experiences
of the clinician, as opposed to knowledge of cancer behavior and prognosis. This is one of the
reasons underlying the poor prognosis of the disease. Consequently, this signifies the importance of
understanding genomic variations in pancreatic cancer to enable clinicians to provide diagnostic and
prognostic information to pancreatic cancer patients individually [89]. A ground breaking genomic
analysis study on 24 distinct pancreatic cancers by Jones et al., uncovered an average of 63 genetic
mutations per cancer, covering 12 different signal transduction pathways. The study emphasized the
concept of the genetically heterogeneous nature of pancreatic cancer, which could in part account for
its evident resistance to therapy and varying responses to treatment. As such, there is dire need for
development of novel therapeutic strategies against specific genetic aberrations in order to enhance
patient impact [105]. Of late, the use of genetic variants as biomarkers to guide targeted therapeutic
approaches has been shown in varying types of cancer within the clinical setting. Conversely, clinical
efforts steered by genetic variations have not yet been realized in pancreatic cancer. Moreover, it has
been considered challenging to develop treatments to directly target the genetic abnormalities of the
four major driver genes in pancreatic cancer: KRAS, TP53, CDKN2A and SMAD4 due to a number of
reasons such as multifunctionality and location within the cell [106]. Despite this, some promising
results have been demonstrated, thus there are still ongoing efforts to develop novel gene-profile based
therapeutic strategies in order to actualize precision medicine for pancreatic cancer [107].
In this part, we discuss the implications of genomic variations on pancreatic cancer diagnosis and
treatment and recent advances in this field.
5.1. Diagnostic Biomarkers
The identification of biomarkers increases diagnostic accuracy and facilitates the classification of
cancer subtypes. The carbohydrate antigen (CA 19-9) in serum is the most sensitive diagnostic marker
of pancreatic cancer with 80% accuracy in clinics to date. Unfortunately, the principal limitation of this
marker is that it has been shown to be elevated in patients with non-malignant obstructive jaundice and
demonstrates low sensitivity for lesions less than 3 cm [108]. Thus, research into the discovery of new
diagnostic markers is ongoing, especially for early diagnosis of pancreatic cancer. A review regarding the
progress of early diagnosis for pancreatic cancer is published in this particular issue [109].
Telomerase activity has proven to be the most reliable diagnostic marker in pancreatic juice (PJ)
samples as it can distinguish PDAC from chronic pancreatitis [75,110]. Moreover, Vascular endothelial
growth factor (VEGF) A levels are also able to distinguish serous cystic neoplasms (SCN) from mucinous
pancreatic cysts despite similar imaging results [111]. Mucinous pancreatic cysts, but not SCN, have the
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potential to progress to invasive pancreatic adenocarcinoma. Thus, levels of VEGFA, as a marker, could
stratify patients that require surveillance or surgical interventions as well reduce expenses.
Through the study of genomic variations, distinct subtypes of pancreatic cancer have been
defined. In particular, Bailey et al., recently analyzed the expression of 32 recurrently mutated
genes in 456 PDAC patients and identified four subtypes: (1) squamous; (2) pancreatic progenitor;
(3) immunogenic and (4) aberrantly differentiated endocrine exocrine (ADEX) [13]. Each subtype has
varying molecular evolutions and responses to therapy. Similarly, Collissonet et al., also categorized
PDAC into three subtypes based on molecular markers expressed in cancer cell lines: (1) classical,
(2) quasi-mesenchymal (QM), and (3) exocrine-like. They also presented evidences of clinical outcome
and therapeutic response differences between them [112]. QM-PDAC subtype lines were, on average,
more sensitive to gemcitabine than classical subtypes while erlotinib was more effective in classical
subtype cell lines. Hence, this evidence reinforces that classification of subtypes of pancreatic cancer
can present clinicians with the avenue to provide personalized medicine approaches by stratifying
patients for appropriate treatments based on their tumor subtype.
5.2. Prognostic Biomarkers
Prognostic biomarkers can aid clinicians in determining the risk of relapse and disease progression
post-therapy. KRAS, TP53, CDKN2A and SMAD4 are the four major driver genes in pancreatic cancer.
Their status and the extent to which they coexist in an individual patients indicate disease progression
and patient survival [113]. For example, Chen et al., demonstrated that survival of unresectable
pancreatic cancer patients with KRAS mutations was poorer than patients with wild-type KRAS gene
(3.9 months vs. 10.2 months, p < 0.001) [114]. Additionally, studies conducted by Xiang et al., showed
that PDAC patients with mutant TP53R172H and upregulated CAVIN1 represented the patient group
with the shortest survival time after resection [115]. Furthermore, a recent study highlighted that
PDAC patients with the expression of normal CDKN2A have better overall survival after curative
resection [116]. Also, it has recently been shown that patients with loss of SMAD4 have significantly
poorer disease-free survival (mean 57.4 months vs. mean 17.6 months, p = 0.006) [117].
Moreover, other genes aside from the four major driver genes can also predict the postoperative
survival of pancreatic cancer patients. For example, Kornmannet et al., established that patients with
lower expression of CCND1 had a median survival of 15.5 months compared with 6.5 months in
patients with higher levels (p < 0.007) [118]. Furthermore, loss of 18q22.3/deletion of the CPGL gene
has been elucidated as a poor prognostic marker in resected pancreatic cancer. Functional studies
suggest that the CPGL gene is a growth suppressor gene in pancreatic cancer [119]. Additionally,
SNPs of DNA mismatch repair (MMR) genes have the potential to predict patients’ clinical response
to chemoradiotherapy and also can be prognostic markers for tumor respectability and resectable
pancreatic cancer patients’ overall survival [120]. Moreover, Sausenet al., recently conducted large-scale
genomic analyses of 24 PDAC tumors. The studies revealed that 20% of the patient samples displayed
somatic mutations in chromatin-regulating genes, including MLL, MLL2, MLL3 and ARID1A, and these
mutations correlated with improved survival. Overall, these studies establish genetic predictors of
prognosis for pancreatic cancer and provide new explorative avenues for therapeutic intervention.
5.3. Exploiting Genetic Variations to Improve Patient Responses to Gemcitabine
Currently, gemcitabine alone or in combination remains the first line therapy for advanced
pancreatic cancer. However, response rates vary widely between patients, with many patients being
insensitive to the drug [121]. This has paved the way for research into how genetic aberrations
in pancreatic cancer impact on patient responses to gemcitabine. Traditionally, the emphasis in
pharmaco genetic studies has been placed on genes in the gemcitabine metabolism pathways.
These studies revealed that either expression of those genes or single nucleotide polymorphisms
(SNPs) within them could only partially account for the observed variation in drug response [122].
Recently, Ellsworth et al., implicated FK506 binding proteins 5 (FKBP5), an immunophilin involved in
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protein folding, as a potential novel biomarker for predicting patient response rates to gemcitabine.
The group conducted functional genomics studies which suggested that the rs73748206 SNP in
FKBP5, may contribute to the varied patient responses to gemcitabine through upregulating FKBP5
by greater binding to glucocorticoid receptor (GR), an established regulator of FKBP5 expression.
Similarly, through genotype-phenotype association analyses, Li et al., identified that four SNPs
positioned in chromosomes 1, 3, 7 and 20, respectively, correlated with overall survival in patients who
underwent treatment with gemcitabine. Further studies by the group delineated that two imputed
SNPS, rs9637468 found in KRT8P35 and rs4925193 in CDH4 were associated with overall survival
during gemcitabine therapy. In particular, three pancreatic cancer cells with CDH4-knockdown were
significantly desensitized to treatment with gemcitabine, suggesting that CDH4 may plays a role
in differing responses to gemcitabine [123]. Moreover, recent genome-wide pleiotropy scan and
transcriptome studies have established that the HNF1 homeobox A (HNF1A) gene has a key role in the
progression of pancreatic cancer. Also, melanoma inhibitory activity 2 (MIA2) gene is one of the target
genes of HNF1A. A recent study indicated that HNF1A and MIA2 are expressed in a subset of human
PDAC tissues and in vitro studies demonstrated that HNF1A induced MIA2. Of particular relevance
is the group’s finding that PDAC cell lines that expressed MIA2I141M, a common germline variant
of MIA2, had enhanced chemosensitivity to gemcitabine. This data could shed light on identifying
subgroups of PDAC patients who may be more likely to benefit from gemcitabine treatment [124].
Overall, these data highlight novel biomarkers that may be used to predict responses to gemcitabine
therapy (Figure 2), thus providing insight into strategies to stratify patients for treatment.
Figure 2. Genomic variations in pancreatic cancer that make patients more sensitive to Gemcitabine.
5.4. Therapeutic Inhibition of KRAS
Mutant KRAS plays a significant role in pancreatic cancer progression and in the majority of
cases, oncogenic KRAS has the ability to initiate PDAC. Oncogenic KRAS is found exclusively in
cancer cells with up to 90% of pancreatic cancer cells possessing the mutation [125]. Thus, research
has been heavily invested in discovering treatments which target mutant KRAS in order to inhibit
its effects (Table 2), however as yet, no KRAS inhibitors have progressed to usage in clinical settings.
Directly inhibiting KRAS was initially considered to be an attractive approach for KRAS mutant
PDAC, thus several efforts have been made to develop therapeutics to achieve this. Initially,
farnesyl-transferase inhibitors (FTIs) were deemed to be the “wonder drug” for KRAS-driven PDAC.
FTIs act by inhibiting farnesyl-transferase, which has the downstream effect of impeding KRAS
activation, this is because KRAS is farnesylated, which enables it to interact with the membrane and
become activated by RAS-guanine nucleotide exchange factors (GEFs). Despite an array of FTIs being
investigated in clinics, such as Lonafarnib and Tipifarnib, the drugs have not demonstrated promising
results. This could be attributed to variations among the three Ras proteins, as preclinical studies that
generated enthusiasm for FTIs were conducted on HRAS-driven tumors. KRAS, as opposed to HRAS
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can seek alternative post-translational modifications for activation, such as being geranyl-geranylated
once farnesyl-transferase is blocked. This provides KRAS with an alternate mechanism to enable
association with the membrane and activation of its proteins [126]. Nevertheless, ongoing efforts
in KRAS inhibition are still being pursued through other routes such as preventing KRAS from
reaching cell membranes. In particular, S-trans, trans-FarnesylthiosalicylicAcid (FTS, salirasib) which
inhibits RAS-dependent cell growth by dislodging all isoforms of RAS including mutant RAS, from the
plasma membrane [29,127] has been investigated in several preclinical and phase II and III clinical
trials and has shown some promise in pancreatic cancer. Another such small molecule inhibitor is
Deltarasin, which acts by interacting with the farnesyl-binding pocket of PDEδ. PDEδ associates with
farnesylated-KRAS and enables it to be translocated to the membrane. Hence, Deltarasin enables
KRAS to be farnesylated but halts it from reaching the membrane. A recent study demonstrated that
Deltarasin did indeed prevent KRAS from associating with the plasma membrane and decreased the
proliferation of KRAS-driven PDAC cell lines [128].
In addition, mutations in KRAS hinder its ability to allow hydrolysis of GTP to GDP, hence forcing
the protein to be locked in an active conformation. Thus, directly inhibiting the GTP-binding site
of KRAS would be an ideal method to restrict KRAS signaling. However, small molecule inhibitors
which have been investigated to date have not amounted to clinical success, thus KRAS is not
generally considered to be druggable. This has driven efforts to investigate methods to indirectly
target KRAS through downstream effectors in KRAS signaling pathways [125,129]. The MEK/MAPK
and PI3K/AKT/mTOR pathways represent favorable pathways to be targeted therapeutically because
they are the prevalent downstream pathways of KRAS and already have established clinical inhibitors
available. Firstly, even though many MEK inhibitors, including CI-1040 and PD0325901 have been
studied in clinical trials, they have been unsuccessful in delivering significant results. Moreover,
drug targeting the PI3K/AKT/mTOR pathways, such as Everolimus, an inhibitor of mTOR, was able
to impede tumor growth in vivo [130], however in a phase II study, it demonstrated little clinical
success in PDAC patients resistant to gemcitabine. In contrast, LY294002, an inhibitor of PI3K was
recently shown to promote apoptosis in vitro and prevent tumor proliferation in vivo. In addition,
it was recently elucidated that cancers with activated KRAS and oncogenic TP53 were unable to
respond to mTOR inhibitors, conversely, tumors with KRAS activation and PTEN loss did respond
to mTOR inhibitors [106]. Furthermore, Collissonet et al., recently reported that blocking MEK1/2 in
orthotopically transplanted human and mouse PDAC cell lines potently prevented cancer cell growth.
The study also highlighted that compensatory PI3K/AKT pathway activation occurred upon MEK1/2
inhibition, which can be justified by the known crosstalk between MEK and PI3K pathways in mutant
KRAS tumors.This could be solved by a combinatory treatment of MEK1/2 with AKT inhibition,
which has shown very impressive outcomes in preclinical studies in non-small cell lung cancer [129].
However, it is yet to be determined whether combining MAPK and PI3K pathway inhibition will
provide synergistic effects in KRAS-driven endogenous PDAC in vivo [130].
Table 2. Mutant KRAS targeted drugs for pancreatic cancer treatment
Drugs Mechanism Efficacy
FTIs (Lonafarnib and Tipifarnib) Inhibiting farnesylation of KRAS Not promising
FTS, salirasib Preventing KRAS from reachingcell membranes Promising
Deltarasin
Enabling KRAS to be farnesylated
but halting it from reaching the
membrane
Decreasing the proliferation of
KRAS-driven PDAC cell lines
CI-1040 and PD0325901 Inhibiting MEK/MAPK pathwaydownstream of KRAS Not significant
LY294002 Inhibiting PI3K pathwaydownstream of KRAS
Promoting apoptosis in vitro and
preventing tumor proliferation
in vivo
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5.5. Exploring Immunotherapy for Pancreatic Cancer Based on Genetic Variations
Immunotherapy has emerged as a highly promising and rapidly evolving strategy for cancer
patient prognosis and has already shown clinical successes in melanoma and lung cancer patients.
Despite this, immunotherapies for PDAC have not yet yielded much clinical benefit when administered
as single agents. This low efficacy could be attributed to the highly fibrotic and immunosuppressive
tumor microenvironment, which is prevalent in most human PDACs [131,132]. Nevertheless,
the favorable clinical outcomes that the therapy poses have maintained considerable research efforts
into immunotherapy for pancreatic cancer (Table 3).
Firstly, the identification of tumor antigens has resulted in the development of more specific and
potent cancer vaccines. These vaccines are composed of the specific tumor antigen and are administered
in order to augment the host’s natural immune defence against the antigen [133]. Of pancreatic cancer
antigens, MUC1 has received the most interest due to its specific upregulation in pancreatic cancer
cells and its correlation with tumor invasion and metastasis. However, clinical trials to date using
MUC1-containing vaccines have not presented efficacious results, although the studies have shown
an interesting association between MUC1 and immune biomarkers including CD38 (a marker for
activated lymphocytes) and reduced T-regulatory cells (T-regs) levels. In addition, oncogenic KRAS
has also received abundant attention in the field of cancer vaccines and was utilized as the first
peptide vaccine to be studied in clinical trials targeting KRAS mutant pancreatic cancer. In similitude
to MUC1-containing vaccines, vaccination approaches using mutant RAS peptides have not shown
clinical benefits, however, more novel vaccination peptides are currently being analyzed clinically [98].
Furthermore, adoptive T-cell therapy represents another innovative immunotherapy for pancreatic
cancer. This treatment involves expanding and activating of the patient’s T-cells Ex Vivo and then
re-infusing them back into the patient. Adoptive T-cell transfer can be categorized into three groups
depending on the source and method adopted for T-cell activation: (1) tumor infiltrating lymphocytes
(TILs); (2) engineered T-cells which express a specific cancer T-cell receptor (TCR); and (3) T-cells
which express a chimeric antigen receptor (CAR). Several targets have been studied in relation to
adoptive T-cell therapy for pancreatic cancer; however the efficacy of this treatment is yet to be
determined for these particular patients. One of these therapeutic targets includes MUC1 and a study
that explored MUC1-specific cytotoxic T-lymphocytes in 20 patients demonstrated 19% 3 year-survival
in those patients with resectable tumors, as well as elevated levels of effector lymphocytes and reduced
T-regs [134]. Similarly, another molecule of interest is Mesothelin, a 40 kDa cell surface glycoprotein
which is overexpressed in pancreatic cancer and is thought to be involved in metastasis. Initial data
from human clinical trials have demonstrated that CAR T-cells specific for Mesothelin are well-tolerated
and possess potential efficacy against pancreatic cancer [135].
Moreover, tumor-targeted oncolytic viruses (TOVs) have also appeared as a promising therapeutic
for cancer immunotherapy, yet clinical successes have not been significant. The immunosuppressive
tumor microenvironment might be a major factor for inhibiting TOV-induced anti-tumor immune effects.
Principally, TOVs is designed to selectively eliminate cancer cells and produce systemic anti-tumor
effects such as promoting long lasting anti-tumor immunity [5]. An example of this is Reolysin, a live
replication-competent form of the reovirus serotype 3 Dearing strain. Reolysin has shown therapeutic
efficacy in pancreatic cells with KRAS mutations, owing to its ability to replicate specifically in cells
with activated KRAS ultimately resulting in lysis of KRAS-activated cancer cells [130].
Furthermore, monoclonal antibody (mAbs)-based immunotherapies have shown clinical efficacy
in many cancers and have become a standard element of cancer therapeutics. MAbs elicit their
anti-tumor effects through multiple methods, including direct targeting of the cancer cells; altering the
host immune response; redirecting host immunity towards the cancerous cells; and delivering cytotoxic
materials [136]. As previously mentioned, IL-17 plays a role in pancreatic cancer development often
via immunosuppression, which has led to further studies to target and neutralize the cytokine for
therapeutic benefit using mAbs [100]. Wu et al., recently elucidated that in pancreatic cancer patients,
upregulation of IL-17 receptor B (IL-17RB) was highly associated with postoperative metastasis and
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negatively correlated with progression-free survival. Ex Vivo studies supported this discovery as it
was demonstrated that IL-17RB and its ligand, IL-17 are vital elements for pancreatic cancer metastasis
and progression. The study also highlighted a novel therapeutic approach for tackling pancreatic
cancer through treatment with a newly derived monoclonal antibody against IL-17RB, which inhibited
metastasis and improved survival in a mouse xenograft model [137,138]. Similarly, McAllister et
al., revealed that monoclonal antibodies designed to neutralize IL-17 receptor A/IL-17 slowed the
development of PanINs. These studies exemplify the importance of IL-17 inhibition as a targeted
therapeutic approach for pancreatic cancer.
An abundance of recent research has given credence to the fact that the efficacy of immunotherapies
is enhanced when deployed in combination. A recent study demonstrated that focal adhesion kinase
1 (FAK1) inhibitors strengthened the anti-tumor potency of adoptive T-cell transfer therapy and
anti-programmed cell death protein 1 (PD-1) checkpoint inhibitors (in combination with gemcitabine).
The study revealed that FAK1 activity was heightened in human PDAC cells and was associated with
elevated levels of fibrosis and poor CD8+ cytotoxic T-cell infiltration, which have previously been
identified as barriers to the success of immunotherapies. The group found that FAK inhibition using
VS-4718 overcame the fibrotic and immunosuppressive PDAC tumor microenvironment, thus enabling
the unresponsive KPC mouse model to be responsive to the immunotherapies [131]. Furthermore, another
receptor implicated in immune modulation of pancreatic cancer is C-X-C chemokine receptor type 2
(CXCR2). Steele et al., recently determined that CXCR2 signaling is upregulated in neutrophils and
myeloid-derived suppressor cells and this was associated with poor prognosis in PDAC. However,
neutralization of CXCR2 via a clinically relevant CXCR2 small-molecule inhibitor prolonged tumor-free
survival in mice models. Importantly, inhibition of CXCR2 enhanced sensitivity to anti-PD-1 therapy and
this combination therapy improved T-cell infiltration and promoted survival [139,140].
Antibody therapy against immune-checkpoint, such as anti-CTLA-4, PD1 or PD-L1 antibodies,
has achieved some impressive success in recent years, in particular in some patients with metastatic
melanoma and lung cancer. This kind of therapy has demonstrated the possibility of relieving immune
suppression in PDAC. We have recently summarized the progress and challenging in this field [5].
The clinical benefits of immunotherapy seen in melanoma and lung cancer warrant further
studies within the pancreatic cancer field. Investigations are currently ongoing with the knowledge
that combining immunotherapies with other immunotherapies such as immune checkpoint inhibitors
as well as with chemotherapy may enhance treatment efficacy through synergistic effects [98].
Table 3. Immunotherapies for pancreatic cancer
Immunotherapies Examples Mechanism




Expanding and activating of the patient’s T-cells
ex-vivo and then re-infusing them back into the
patient to kill tumor cells
Engineered T-cells which






viruses (TOVs) Reolysin, etc.
Selectively eliminating cancer cells and
producing systemic anti-tumor effects such as
promoting long lasting anti-tumor immunity
Monoclonal antibody IL17RB; IL17RA, etc.
Direct targeting of the cancer cells; altering the
host immune response; redirecting host
immunity towards the cancerous cells;
and delivering cytotoxic materials
Immune checkpoint therapy CTLA4; PD1, etc. Enhancing T cells function
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6. Conclusions
Undoubtedly, the urgent need for novel and innovative therapeutics to tackle pancreatic cancer is
of paramount importance in order to significantly improve prognosis of this almost universally lethal
and devastating disease. The study of genomic variations is at the forefront of enhancing pancreatic
cancer patient impact by providing an avenue for precision medicine. Understanding genomic
variations in pancreatic cancer is crucial, as they are known to contribute to pancreatic carcinogenesis
and provide fundamental knowledge for new and effective treatment strategies. Although it is well
recognized that KRAS, CDKN2A, SMAD4 and TP53 are major driver genes in pancreatic cancer, thus far
these genetic alterations have not been exploited effectively for therapeutic benefits. Hence, it is vital
that further research is conducted into understanding how to target these major driver genes and their
signaling pathways using immunotherapy and chemotherapy to enhance therapeutic benefits.
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